AtaiBeckley Inc. shares surged sharply in pre-open trading, rising 52.2% after Bloomberg reported that Eli Lilly is in advanced negotiations to acquire the psychedelic-focused drugmaker at a premium to its current market value. Reports indicated an announcement could come as soon as this week.
The potential buyer, an Indianapolis-based pharmaceutical company, is reportedly discussing terms that would top AtaiBeckley’s market capitalization, which has climbed to roughly $2 billion after the company's stock more than doubled over the past year.
Multiple outlets relayed that Eli Lilly is in talks to acquire AtaiBeckley, with one report noting the possibility of a near-term announcement. The prospect of a deal drew rapid commentary from Wall Street and venture capital participants outlining the strategic implications and likely valuation dynamics.
Strategic rationale cited by analysts
BMO Capital Markets analysts said a purchase would provide an immediate platform of rapid-acting psychedelic-based treatments and extend the buyer’s neuroscience footprint into areas such as treatment-resistant depression and other challenging psychiatric conditions.
Venture capital perspective
Magnus Sigurdsson, co-founder of Systematic Ventures and partner at Iron Pine Ventures, wrote on X that the discussions appear to reflect the conclusion of a structured banking process AtaiBeckley began around its lead candidate, BPL-003, in March. He estimated a likely takeover price in the range of $9 to $11 per share.
Observers also linked the takeover interest to broader momentum in psychedelic medicines following commercial success by other treatments and improving clinical trial outcomes.
Market context and regulatory backdrop
The rally occurred while the major U.S. indexes were essentially flat - with the S&P 500, Dow Jones and NASDAQ little changed - indicating the move was specific to AtaiBeckley rather than driven by broader market action.
Investors had already pushed ATAI higher on Tuesday afternoon as they digested final FDA guidance for psychedelic-drug trials. The guidance expects two monitors to remain with a patient for the duration of a treatment session, a detail that makes AtaiBeckley’s roughly two-hour clinic treatment model more relevant when assessing operating costs.
Sector ripple effects
The acquisition reports triggered a sympathy rally among sector peers, with shares of GH Research rising in premarket trading. RBC Capital Markets analyst Brian Abrahams identified GH Research as having the clearest read-across to the potential transaction.
The combination of takeover interest from a large pharmaceutical company, supportive analyst commentary on strategic fit, and a regulatory environment viewed as increasingly relevant to clinic-based treatment models created a layered catalyst for the pre-market surge. The heightened activity has pushed the stock well above its prior 52-week high of $6.75.